Business
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy
Waverley Pharma Announces Grant of Market Authorization for Pemetrexed in Spain and Bortez...
About this update from Waverley Pharma, Inc.
[{"type":"text","content":"\n\n\n\nWaverley Pharma Announces Grant of Market Authorization for Pemetrexed in Spain and Bortezomib in Italy\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, MB, Aug. 25, 2020\n\n\n\nWINNIPEG, MB, Aug. 25, 2020 /CNW/ - Waverley Pharma Inc. (\"Waverley Pharma\" or the \"Company\") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization for Pemetrexed in Spain and Bortezomib in Italy.\nAbout Pemetrexed\nPemetrexed is an injectable chemotherapy product used in the treatment of pleural mesothelioma and non-small cell lung cancer along with other indications. The Company has obtained marketing authorization for this product in numerous countries and is in the process of filing for market authorization in additional countries across Europe.\nAbout Bortezomib\nBortezomib is an injectable chemotherapy product used to treat multiple myeloma and mantle cell lymphoma along with other indications. The Company has obtained marketing authorization for this product in numerous countries and is in the process of filing for market authorization in additional countries across Europe.\nAbout Waverley Pharma\nWaverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective, and affordable cancer therapeutics in the European Union, United Kingdom and North American market. The Company, through its subsidiary, is currently selling three generic oncology products in the United Kingdom, namely capecitabine, temozolomide and erlotinib. In addition, the Company is developing two generic oncology products in Europe, namely pemetrexed and bortezomib and additional products in the United States. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. For more information on Waverley Pharma please visit www.waverleypharma.com.\nNeither the TSX Venture Exchange nor its Regula...